Cargando…

Enhanced anti-HCV activity of interferon alpha 17 subtype

BACKGROUND: Pegylated interferon alpha 2 (a or b) plus ribavirin is the most effective treatment of chronic hepatitis C but a large proportion of patients do not respond to therapy. So, it is interesting to improve the treatment efficacy. Interferon alpha is a type I interferon composed of 12 differ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dubois, Aurelie, François, Catherine, Descamps, Veronique, Fournier, Carole, Wychowski, Czeslaw, Dubuisson, Jean, Castelain, Sandrine, Duverlie, Gilles
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697159/ https://www.ncbi.nlm.nih.gov/pubmed/19493343 http://dx.doi.org/10.1186/1743-422X-6-70

Ejemplares similares

A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies
por: Fournier, Carole, et al.
Publicado: (2007)

Permissivity of Primary Human Hepatocytes and Different Hepatoma Cell Lines to Cell Culture Adapted Hepatitis C Virus
por: Helle, Francois, et al.
Publicado: (2013)

Correction: Permissivity of Primary Human Hepatocytes and Different Hepatoma Cell Lines to Cell Culture Adapted Hepatitis C Virus
por: Helle, Francois, et al.
Publicado: (2019)

Hepatitis C Virus Resistance to Carbohydrate-Binding Agents
por: Izquierdo, Laure, et al.
Publicado: (2016)

Indoleamine 2,3-Dioxygenase Is Involved in Interferon Gamma’s Anti-BKPyV Activity in Renal Cells
por: Fiore, Tony, et al.
Publicado: (2020)

BK Polyomavirus Micro-RNAs: Time Course and Clinical Relevance in Kidney Transplant Recipients
por: Demey, Baptiste, et al.
Publicado: (2021)

Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals
por: Brochot, Etienne, et al.
Publicado: (2020)

BK Polyomavirus Hijacks Extracellular Vesicles for En Bloc Transmission
por: Handala, Lynda, et al.
Publicado: (2020)

Apolipoprotein(a) inhibits hepatitis C virus entry through interaction with infectious particles
por: Oliveira, Catarina, et al.
Publicado: (2017)

Simeprevir for the treatment of hepatitis C virus infection
por: Izquierdo, Laure, et al.
Publicado: (2014)

Comparison of different serological assays for SARS-CoV-2 in real life
por: Brochot, Etienne, et al.
Publicado: (2020)

Biology of the BKPyV: An Update
por: Helle, Francois, et al.
Publicado: (2017)

Longitudinal Analysis and Comparison of Six Serological Assays up to Eight Months Post-COVID-19 Diagnosis
por: Aubry, Aurélien, et al.
Publicado: (2021)

Humoral anti-SARS-CoV-2 immune response after two doses of Comirnaty vaccine in nursing home residents by previous infection status
por: Helle, François, et al.
Publicado: (2022)

Dynamic profile for the detection of anti-SARS-CoV-2 antibodies using four immunochromatographic assays
por: Demey, Baptiste, et al.
Publicado: (2020)

The Hepatitis C Virus Glycan Shield and Evasion of the Humoral Immune Response
por: Helle, François, et al.
Publicado: (2011)

Hepatitis C Virus Replication and Golgi Function in Brefeldin A-Resistant Hepatoma-Derived Cells
por: Farhat, Rayan, et al.
Publicado: (2013)

Epidemiology and seasonality of acute respiratory infections in hospitalized children over four consecutive years (2012–2016)
por: Fillatre, Adrien, et al.
Publicado: (2018)

NS2 Protein of Hepatitis C Virus Interacts with Structural and Non-Structural Proteins towards Virus Assembly
por: Popescu, Costin-Ioan, et al.
Publicado: (2011)

Alginate Hydrogel Protects Encapsulated Hepatic HuH-7 Cells against Hepatitis C Virus and Other Viral Infections
por: Tran, Nhu-Mai, et al.
Publicado: (2014)

BK Polyomavirus bkv-miR-B1-5p: A Stable Micro-RNA to Monitor Active Viral Replication after Kidney Transplantation
por: Demey, Baptiste, et al.
Publicado: (2022)

Shared and Unique Features of Human Interferon-Beta and Interferon-Alpha Subtypes
por: Wittling, Megen C., et al.
Publicado: (2021)

Different Biological Activities of Specific Interferon Alpha Subtypes
por: Hasenkrug, Kim J., et al.
Publicado: (2019)

Interferon Alpha Therapy in Patients with Chronic Type C Hepatitis: Changes of Serum ALT, Anti-HCV & HCV-RNA
por: Cho, Ho Jun, et al.
Publicado: (1992)

Hepatitis C Virus Improves Human Tregs Suppressive Function and Promotes Their Recruitment to the Liver
por: Ouaguia, Laurissa, et al.
Publicado: (2019)

Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent
por: Hillyer, Philippa, et al.
Publicado: (2012)

Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent
por: Hillyer, P, et al.
Publicado: (2013)

Interferon-alpha Subtype 11 Activates NK Cells and Enables Control of Retroviral Infection
por: Gibbert, Kathrin, et al.
Publicado: (2012)

HCV cure without interferon
por: Bourlière, Marc
Publicado: (2014)

Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro
por: Fénéant, Lucie, et al.
Publicado: (2015)

Acute pericarditis due to pegylated interferon alpha therapy for chronic HCV hepatitis - Case report
por: Popescu, Cristina, et al.
Publicado: (2011)

The CD81 Partner EWI-2wint Inhibits Hepatitis C Virus Entry
por: Rocha-Perugini, Vera, et al.
Publicado: (2008)

Interferon-λ in HCV Infection and Therapy
por: Pagliaccetti, Nicole E., et al.
Publicado: (2010)

Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients
por: Rivero-Juárez, Antonio, et al.
Publicado: (2012)

Effects of Pegylated Interferon Alpha and Ribavirin (pegIFN-α/RBV) Therapeutic Approach on Regulatory T Cells in HCV-Monoinfected and HCV/HIV-Coinfected Patients
por: Grubczak, Kamil, et al.
Publicado: (2021)

The association of CD81 with tetraspanin-enriched microdomains is not essential for Hepatitis C virus entry
por: Rocha-Perugini, Vera, et al.
Publicado: (2009)

Natural leukocyte interferon alpha (Alfaferone) combined with ribavirin in the treatment of patients with HCV-related cirrhosis: our experience
por: Kozielewicz, D., et al.
Publicado: (2011)

A functional selection of viral genetic elements in cultured cells to identify hepatitis C virus RNA translation inhibitors(†)
por: Jaffrelo, Loic, et al.
Publicado: (2008)

Reply to Hasenkrug et al., “Different Biological Activities of Specific Interferon Alpha Subtypes”
por: Schlaepfer, Erika, et al.
Publicado: (2019)

Recent advances in the anti-HCV mechanisms of interferon
por: Huang, Menghao, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_o8pf3ke6u00v9o0n0mtd1ge96d